97 related articles for article (PubMed ID: 22973751)
1. What's new in renal cell carcinoma.
Meng MV; Nelson H
Bull Am Coll Surg; 2012 Aug; 97(8):65-6. PubMed ID: 22973751
[No Abstract] [Full Text] [Related]
2. Predictors of response to targeted therapy in renal cell carcinoma.
Eisengart LJ; MacVicar GR; Yang XJ
Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
[TBL] [Abstract][Full Text] [Related]
3. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.
Chapman AE; Goldstein LJ
Semin Oncol; 1995 Feb; 22(1):17-28. PubMed ID: 7855615
[No Abstract] [Full Text] [Related]
4. Rational therapy for renal cell carcinoma based on its genetic targets.
Messer J; Drabick J; Kaag M
Adv Exp Med Biol; 2013; 779():291-308. PubMed ID: 23288645
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.
Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S
Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215
[No Abstract] [Full Text] [Related]
6. [Targeted therapy for renal cell carcinoma].
Terai K; Horie S
Nihon Jinzo Gakkai Shi; 2016; 58(4):568-72. PubMed ID: 27416700
[No Abstract] [Full Text] [Related]
7. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
[TBL] [Abstract][Full Text] [Related]
8. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Powles T
Clin Genitourin Cancer; 2012 Jun; 10(2):67-8. PubMed ID: 22608779
[No Abstract] [Full Text] [Related]
9. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner TA; Logan T
J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
[No Abstract] [Full Text] [Related]
10. [Research impulses for personalized cancer therapies].
Aktuelle Urol; 2013 Sep; 44(5):349. PubMed ID: 24043531
[No Abstract] [Full Text] [Related]
11. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
[TBL] [Abstract][Full Text] [Related]
12. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
Rini BI
Clin Cancer Res; 2010 Mar; 16(5):1348-54. PubMed ID: 20179240
[TBL] [Abstract][Full Text] [Related]
13. A prognostic model for patients with metastatic renal cell cancer: what's new?
Di Lorenzo G
Eur Urol; 2011 Jul; 60(1):57-9. PubMed ID: 21194831
[No Abstract] [Full Text] [Related]
14. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
Kirkali Z
BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
[TBL] [Abstract][Full Text] [Related]
15. [Biomarker for molecular targeting therapy against renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
[No Abstract] [Full Text] [Related]
16. Targeted therapy: An elusive cancer target.
Brown C
Nature; 2016 Sep; 537(7620):S106-8. PubMed ID: 27626779
[No Abstract] [Full Text] [Related]
17. [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
Tomita Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):907-10. PubMed ID: 21677480
[TBL] [Abstract][Full Text] [Related]
18. Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer.
Srinivasan R; Linehan WM
J Clin Oncol; 2005 Jan; 23(3):410-2. PubMed ID: 15572728
[No Abstract] [Full Text] [Related]
19. Sequential use of targeted agents in the treatment of renal cell carcinoma.
Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for renal cell carcinoma.
Varella L; Rini BI
Expert Opin Emerg Drugs; 2010 Sep; 15(3):343-53. PubMed ID: 20443750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
